Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J. Versluis, F. E. M. In 't Hout, R. Devillier, W. L. J. van Putten, M. G. Manz, M-C Vekemans, M-C Legdeur, J. R. Passweg, J. Maertens, J. Kuball, B. J. Biemond, P. J. M. Valk, B. A. van der Reijden, G. Meloni, H. C. Schouten, E. Vellenga, T. Pabst, R. Willemze, B. Lowenberg, G. OssenkoppeleF. Baron, G. Huls, J. J. Cornelissen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)26-33
Number of pages8
JournalLeukemia
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 2017

Keywords

  • ACUTE MYELOID-LEUKEMIA
  • STEM-CELL TRANSPLANTATION
  • MINIMAL RESIDUAL DISEASE
  • 1ST COMPLETE REMISSION
  • INTERNAL TANDEM DUPLICATION
  • ACUTE MYELOGENOUS LEUKEMIA
  • NO-DONOR ANALYSIS
  • UK MRC AML-10
  • REDUCED-INTENSITY
  • ALLOGENEIC TRANSPLANTATION

Cite this

Versluis, J., 't Hout, F. E. M. I., Devillier, R., van Putten, W. L. J., Manz, M. G., Vekemans, M-C., Legdeur, M-C., Passweg, J. R., Maertens, J., Kuball, J., Biemond, B. J., Valk, P. J. M., van der Reijden, B. A., Meloni, G., Schouten, H. C., Vellenga, E., Pabst, T., Willemze, R., Lowenberg, B., ... Cornelissen, J. J. (2017). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1), 26-33. https://doi.org/10.1038/leu.2016.183